Free Trial

Cellectar Biosciences (CLRB) Earnings Date, Estimates & Call Transcripts

Cellectar Biosciences logo
$3.07 -0.07 (-2.20%)
As of 12:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cellectar Biosciences Earnings Summary

Cellectar Biosciences posted Q1 2026 earnings on May 14, 2026, reporting an EPS of -$1.33, which topped the consensus estimate of -$1.89 by $0.56. With a trailing EPS of -$6.66, Cellectar Biosciences' earnings are expected to grow next year, from ($2.34) to ($1.93) per share.

Upcoming Q2
Earnings Date
Aug. 13Before Market OpensEstimated
Consensus EPS
(May. 14)
-$1.89
Actual EPS
(May. 14)
-$1.33 Beat By $0.56

Q1 2026 Earnings Resources

CLRB Upcoming Earnings

Cellectar Biosciences' next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Get Cellectar Biosciences Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectar Biosciences and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

CLRB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Cellectar Biosciences Analyst EPS Estimates

Current Year EPS Consensus Estimate
($2.34) EPS
Next Year EPS Consensus Estimate
($1.93) EPS

Cellectar Biosciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/13/2026
(Estimated)
--------
5/14/2026Q1 2026-$1.8850-$1.33+$0.5550-$1.33$8.00M-
3/4/2026Q4 2025-$1.19-$0.53+$0.66-$0.53--
11/13/2025Q3 2025-$1.91-$1.41+$0.50-$1.41--
8/14/2025Q2 2025-$3.60-$3.39+$0.21-$3.39--
5/13/2025Q1 2025-$5.10-$3.90+$1.20-$0.14--
10/29/2024Q3 2024--$15.30--$0.84--

Data powered by Fiscal.ai.

Cellectar Biosciences Earnings - Frequently Asked Questions

Cellectar Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 13th, 2026 based off last year's report dates. Learn more on CLRB's earnings history.

In the previous quarter, Cellectar Biosciences (NASDAQ:CLRB) reported ($1.33) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.89) by $0.56. Learn more on analysts' earnings estimate vs. CLRB's actual earnings.

The conference call for Cellectar Biosciences' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Cellectar Biosciences' latest earnings report can be read online.
Read Transcript

Cellectar Biosciences (NASDAQ:CLRB) has a recorded net income of -$21.79 million. CLRB has generated -$6.66 earnings per share over the last four quarters.

Cellectar Biosciences' earnings are expected to grow from ($2.34) per share to ($1.93) per share in the next year.


This page (NASDAQ:CLRB) was last updated on 5/29/2026 by MarketBeat.com Staff.
From Our Partners